A number of clinical trials are underway globally for ALS; a comprehensive listing of trials in the US can be found at ClinicalTrials.gov.
Thalidomide and Lenalidomide have shown efficacy in protecting motor neurons in transgenic (G93A) mice.
KNS-760704 (Dexpramipexole) is under clinical investigation in ALS patients. It is hoped that the drug will have a neuroprotective effect. It is one enantiomer of pramipexole, which is approved for the treatment of Parkinson's disease and restless legs syndrome. The single-enantiomer preparation is essentially inactive at dopamine receptors, is not dose limited by the potent dopaminergic properties of pramipexole. Results of a Phase II clinical trial conducted by Knopp Neurosciences and involving 102 patients were reported in 2010; the trial found a dose-dependent slowing in loss of function. A larger phase II trial conducted by Biogen found the drug to be safe, well tolerated, and associated with a dose-dependent slowing in the decline of ALS.
A Phase II trial on talampanel was completed by Teva Pharmaceutical Industries in April 2010 however it was found to be negative for treatment viability.
Read more about this topic: Amyotrophic Lateral Sclerosis
Famous quotes containing the word research:
“The great question that has never been answered, and which I have not yet been able to answer, despite my thirty years of research into the feminine soul, is What does a woman want? [Was will das Weib?]”
—Sigmund Freud (18561939)